Report : 3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms (Tablets, Capsules, Multi Drug Implant, Nanoparticles, Solutions, Others); Technology (Inkjet Printing, Direct Write, Zip Dose, Thermal Inkjet Printing, Fused Deposition Modeling, Powder Bed Printing, Stereolithography (SLA), Semi Solid Extrusion (SSE)), and Geography
Tablet Segment to Accelerate at a Fast Pace over the Forecast Period
According to The Insight Partners market research study titled “3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms and Technology,” the global 3D printed drugs market is expected to reach US$ 57.03 Mn in 2027 from US$ 28.52 Mn in 2019. The market is estimated to grow at a CAGR of 9.1% from 2020 to 2027. The report provides trends prevailing in the 3D printed drug ecosystem, and the driving factors and restraining factors pertaining to the market.
The global 3D printed drugs market, based on the dosage forms, is segmented into tablets, capsules, multi drug implant, nanoparticles, solutions, and other dosage forms. The tablet segment held the largest share of the market in 2019, and it is further estimated to register the highest CAGR during the forecast period. The growth of the 3D printed drugs market is ascribed to the growing emphasis on personalized medicines and extensive R&D activities.
Leading companies operating in the 3D printed drugs market are Aprecia Pharmaceuticals, LLC, FabRx Ltd, Cycle Pharmaceuticals, GlaxoSmithKline PLC., Astrazeneca, Tvasta, and Merck KGGA, among others.